Surajeet Das Gupta And P B Jayakumar

Stories by Surajeet Das Gupta And P B Jayakumar

Indian retail drug sales jump 10% amid slowdown

Indian retail drug sales jump 10% amid slowdown

Rediff.com   31 Dec 2008

Retail sales of Ranbaxy Laboratories, Cipla, Nicholas Piramal, Lupin and other drug makers have jumped by over 10 per cent in the domestic market despite the sales of generics or copycat versions of patented drugs falling in leading global markets such as the US and Europe.

Ranbaxy to pay damages in price-fixing case

Ranbaxy to pay damages in price-fixing case

Rediff.com   26 Dec 2008

Drug maker agrees to cooperate with Scottish investigation.

Pharma firms eye small buys to stay fit

Pharma firms eye small buys to stay fit

Rediff.com   24 Dec 2008

Dr Reddy's Laboratories, Nicholas Piramal and other Indian drug makers are relying on niche and smaller value, acquisition strategy for growth owing to global slowdown and failure of big-ticket acquisitions in the past.

Glenmark may beat rivals in chemical entity sale

Glenmark may beat rivals in chemical entity sale

Rediff.com   23 Dec 2008

Glenmark plans to start selling its anti-diarrhoea drug, Crofelemer, by the first-half of 2010 across the globe, except in North America, Europe, Japan and China, the company said. The confidence to sell the drug ahead of its rivals comes as the Crofelemer's original developer, Napo Pharmaceutical Inc, recently entered into a tie-up with a US-based drug maker, Salyx, for selling the drug in the US market, paving the way for Glenmark to sell it in the rest of the world.

Slowdown hits medical tool manufacturers

Slowdown hits medical tool manufacturers

Rediff.com   10 Dec 2008

Fearing the slowdown, hospital managements suspended some of their new medical equipment purchase plans," said A Vaidheesh, managing director, Johnson & Johnson Medical, one of the largest medical equipment companies operating in India. India's medical and hospital equipment industry, which consists of multinational players such as Siemens, Philips, Johnson & Johnson, GE Healthcare and home grown Medtronics, has an annual turnover of over Rs 5,000 crore (Rs 50 billion).

Drug cos may gain from polluting status review

Drug cos may gain from polluting status review

Rediff.com   2 Dec 2008

A segment of drug companies such as tablet and capsule makers may benefit from the government's move to review polluting status of these companies, which may help them save costs on pollution control equipment.

Indian drug makers may cut output

Indian drug makers may cut output

Rediff.com   25 Nov 2008

Ranbaxy, Dr Reddy's and other Indian drug makers may cut production as overseas buyers, hurt by the credit crunch, defer export orders. The move could also lower the country's drug exports by at least 10 per cent in the year ending March 2010, industry experts say."Many of our members have been intimated by their importers to stop shipments until further notice," said Venkat Jasti, chairman, Pharmaceutical Exports Promotion Council.

« Prev  |